RLYB News and Press, Rallybio Corporation From 03/15/22

-- Phase 1b proof-of-concept study for RLYB212 in development for the prevention of FNAIT on track to commence in 2Q 2022; initial data expected in 3Q 2022 -- -- First healthy volunteers dosed in Phase 1 study of RLYB116; single dose safety, PK, and PD data expected in 2H 2022...

The following slide deck was published by Rallybio Corporation in conjunction with this event. For further details see: Rallybio (RLYB) Investor Presentation - Slideshow

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rall...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company’s Head o...

-- First subjects dosed in Phase 1 study of RLYB212; proof-of-concept data from subsequent Phase 1b study expected 3Q 2022 -- -- On-track to initiate Phase 1 study of RLYB116 in 1Q 2 022; single dose safety, PK and PD data expected 2H 2022 -- -- Advancing preclinic...

Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...

RLYB211, an IV-administered anti-HPA-1a antibody, demonstrates ability to rapidly and safely eliminate HPA-1a mismatched platelets up to 7 days after administration Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accel...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fire...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a pre-recorded...

Rallybio (NASDAQ:RLYB): Q3 GAAP EPS of -$0.37 beats by $0.52. Cash and cash equivalents were $187M Press Release For further details see: Rallybio EPS beats by $0.52